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Some of their criticisms are probably due to a lack 
of detail in our text. We do receive systematic weekly 
specimens from specific units for bacterial screening, 
but, in our study, we only selected diarrheal stools. As 
stated in Material and Methods, cells for fecal cytotoxin 
detection were examined after overnight and 48-h 
incubation. We observed 50 positive cases; all were 
already positive at  the first reading. No additional 
specimen was positive after 48 h. Fifty-three of the 41 1 
patients had at least one stool positive for a toxigenic 
isolate, giving a prevalence of 13%. 
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I an1 writing about the contents of Supplement 1 to 
Volume 2 (December 1996 [l]). The article by 
Goldstein and his colleagues (p. S40) was excellent and 
I was glad to see that this group is in the growing band 
of investigators who have two guidelines. The diagram- 
matic representations of susceptible and resistant popu- 
lations are excellent and it should be apparent to all 
from these diagrams just what ‘intermediate’ means. 
Table 1 is a good model for providing simple accurate 
information to antibiotic users. The article by Sirot, 
Courvalin and Soussy (p. S5) is also an excellent demon- 
stration of how science should be applied to practical 
everyday procedures in the &agnostic clinical laboratory. 
I was therefore very disappointed that so little 
attention had been given to these papers in the 1996 
Statement on Breakpoints (p. S46). The ‘sensitive’ 
breakpoint for many antibiotics has not been related to 
the normal susceptible population of bacteria. Mode 
MICs are often greatly below the chosen breakpoint, 
so that many strains with low-level resistance are called 
‘fully susceptible’, e.g. to aztreonam, many of the 
cephalosporins and the quinolones. This is because 
the susceptible level has been based on pharmacology 
and not on microbiology (see p. S8). These problems 
become greater if they are applied to more fastidious 
species as exemplified in your footnote 2 (on p. S48) 
regarding Streptococcus pneumoniae. Application of micro- 
biological criteria to microbiological tests give a good 
definition of ‘sensitive’ ii la Goldstein et al. The pharm- 
acologic data should only be applied to defining the 
resistant population. All the other strains are inter- 
mediate. 
A lot of time has been spent trying to simplify 
interpretations of susceptibility testing. I am glad that 
you are adding so many qualifications to the tables. The 
area of susceptibility testing is complex, and the 
exceptions to the rules are many. A move towards 
species-specific guidelines applied to a limited range of 
relevant antibiotics would provide greater clarity and 
fewer exceptions. 
Thank you for your stimulating supplement, w h c h  
1 hope is studied carefully by all those carrying out the 
millions of susceptibility tests performed every day. 
John David Williams 
7 Wiham Road, 
London NW1 3ER. UK 
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